Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Available 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 6Stomach Neoplasms 2Diabetes Mellitus, Insulin-Dependent, 12 2Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Radiotherapy 11pembrolizumab 10Nivolumab 10Doxorubicin 10Magnetic Resonance Spectroscopy 9Specimen Handling 8Ipilimumab 7Cyclophosphamide 7Biopsy 7X-Rays 6Radiation 5Phantoms, Imaging 5Ifosfamide 5talimogene laherparepvec 4cabozantinib 4Nuclear Medicine Department, Hospital 4Irinotecan 4tazemetostat 3selpercatinib 3pazopanib 3liposomal doxorubicin 3Temozolomide 3Etoposide 3ulixertinib 2tislelizumab 2tipifarnib 2palbociclib 2larotrectinib 2ivosidenib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sarcoma × balstilimab × Clear all
NCT04028063 2026-04-20

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

University of Colorado, Denver

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡